Compound ID | 2791
Class: Natural product antibiotic
| Agent Type: | Natural product; Small molecule; Direct acting; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | DNA synthesis inhibitor. DnaN inhibitor |
| Target Pathogen: | Active against Mycobacterium tuberculosis, Mycobacterium phlei, Mycobacterium kansasii, Mycobacterium fortuitum, and Mycobacterium bovis |
| Description: | Natural product from Actinoplanes awajinensis subsp. Mycoplanecinus (rediscovered in genome mining for griselimycin-like biosynthetic gene clusters in actinobacteria); derivatives reported elsewhere; tolerated by mice (400-3,000 mg/kg) when administered subcutaneously or orally |
| Institute where first reported: | Fermentation Research Laboratories, Sankyo Co., Ltd.; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), and Department of Pharmacy, Saarland University, 66123, Saarbrücken, Germany |
| Year first mentioned: | 1983 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/197207 |
| Guide to Pharmacology: | mycoplanecin A |
| Citations: |
|